Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

OSI begins phase I study with glucokinase activator PSN-010

Feb. 17, 2006

AT-2101 receives orphan drug designation for Gaucher's disease

Feb. 17, 2006

Acrux acquires rights to commercialize contraceptive spray

Feb. 17, 2006

NE-180 studied in phase I trial

Feb. 17, 2006

MB-07803 studied in phase I for type 2 diabetes

Feb. 16, 2006

Orphan drug designation for TRX-4 in type 1 diabetes

Feb. 16, 2006

New agents for endocrine-related disorders imparted in recent patent literature

Feb. 16, 2006

Glenmark discovers new drug targeting obesity

Feb. 16, 2006

Eltrombopag begins phase III trials for ITP

Feb. 16, 2006

ProMetic BioSciences cleared for Canadian phase Ib/II study of PBI-1402

Feb. 16, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...